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LETTER TO THE EDITOR Open Access
Epigenetic clocks for gestational age:
statistical and study design considerations
Andrew J. Simpkin, Matthew Suderman and Laura D. Howe*
Abstract
In this letter to the editor, we highlight some concerns with a recently published method to estimate gestational
age at delivery from DNA methylation data. We conduct novel analyses to highlight the implications of different
choices in study design and statistical methods for the prediction of phenotypes from methylation data.
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Letter to the editor
In two recent articles, Bohlin et al. [1] and Knight et al.
[2] develop DNA methylation clocks for gestational age
at delivery (GA) using cord and newborn blood. These
follow from the clock of Horvath [3], which has been
used to obtain a measure of age acceleration, the
discrepancy between estimated and chronological age,
calculated as the residual when regressing one on the
other. Associations between age acceleration and a wide
range of phenotypes have been observed, including
all-cause mortality [4]. The newly developed GA clocks
offer the similar possibility to assess determinants of GA
acceleration (GAA) and associations with subsequent
outcomes. A recent article in this journal used the GA
clock developed by Knight et al. to examine associations
with maternal and offspring characteristics [5].
We applied both GA clocks to cord blood DNA
methylation data from 863 members of the ARIES
cohort [6] in order to test associations of GAA with
birth weight. We observed a strong positive correlation
with the Bohlin GAA estimate (R = 0.20, p = 5.3 × 10−9)
and a comparatively weak correlation with the Knight
estimate (R = 0.055, p = 0.11).
To investigate this discrepancy, we asked how well
both clocks estimated GA in ARIES. Although both were
correlated with GA (Bohlin R = 0.65; Knight R = 0.37),
these correlations are below those reported in their
original publications (Bohlin R = 0.81; Knight R = 0.91).
In the case of Bohlin, this is expected given that their
training and testing sets were drawn from the same
cohort study. This was not the case for Knight. The
scatterplot of the Knight test results (Figure 1b of [2])
suggested that the strong correlation may have been
driven by the inclusion of data for 183 preterm infants
in the test set. We tested this hypothesis by adding these
preterm infants to ARIES, increasing the percentage of
preterm infants (GA < 37 weeks) from 2.8 to 19.8%. As
expected, the correlation of the Knight GA estimate rose
from R = 0.37 in ARIES alone to R = 0.89.
Given the much lower correlation of the Knight
compared to the Bohlin estimate in ARIES, we asked if
the difference could be due to differences between their
training datasets: GA measured using ultrasound
(Bohlin) versus last menstrual period (Knight), mean GA
(Bohlin 39.9; Knight 36.9), training samples (1068 for
Bohlin; 207 for Knight), 450K CpG sites (Bohlin) versus
27K CpG sites (Knight). Most of these predict that
Bohlin will perform best in an average population like
ARIES. We did, however, wonder if the Knight clock
performance could have been improved had more train-
ing samples been used. Whereas the Knight training
dataset consisted of six cohorts with 207 samples, the
testing dataset consisted of > 1000 samples. We also
wondered if the Knight clock consisting of nearly as
many CpG sites (148) as training samples (207) might
have suffered from overfitting.
To explore these concerns, we derived a new GA clock
by fitting elastic nets implementing in the glmnet R
package to the publicly available subset of the Knight
testing and training data restricted to the same 27K CpG
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sites (total n = 400; GSE36642 n = 51; GSE62924 n = 38;
GSE79056 n = 36; GSE80310 n = 24; GSE66459 n = 22;
GSE69633 n = 46; VICS n = 183). The resulting clock
included 193 CpG sites, and its correlation with GA in
ARIES was quite similar to the Knight estimate
(R = 0.56). Both the original Knight clock and our new
clock were correlated with measured GA (R = 0.37) and
with the Bohlin estimate at similar strength (R = 0.49).
Both GAA estimates were also similar (R = 0.49) and
were correlated with the Bohlin GAA estimate at similar
strength (R = 0.35). However, the new GAA estimate
was more strongly correlated with birth weight
(R = 0.09; p = 0.008) compared to the Knight estimate
(R = 0.055, p = 0.11).
Although our clock was less likely to suffer from overfit-
ting (193 CpG sites from 400 samples), we still considered
the ratio of CpG sites to training samples to be quite high.
To investigate, we also generated clocks restricted to 50,
25, and 10 CpG sites. The resulting clocks were still
strongly associated with GA (R = 0.4, 0.33, and 0.25, re-
spectively) and with the default 193-CpG clock (R = 0.82,
0.72, and 0.61, respectively). GAA estimates were similarly
strongly associated with the GAA estimate of the default
clock (R = 0.79, 0.68, and 0.57, respectively) and with birth
weight (R = 0.12, 0.12, and 0.11, respectively). These re-
sults show that 50 CpG sites was sufficient to produce GA
and GAA estimates with optimal performance.
To conclude, care must be taken when deriving and
testing molecular models. Test dataset characteristics
should match the datasets where the model will be later
applied. Training datasets should be as large as possible.
Although it is necessary to reserve data for testing in
order to assess performance, it would be useful if
authors also published a model trained using all avail-
able data. In most cases, the model derived from the
large dataset will be superior. Finally, model sizes should
be restricted to reflect the size of the training data to
avoid overfitting.
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